Patents by Inventor Bart S. Hendriks

Bart S. Hendriks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
    Publication number: 20240358706
    Abstract: Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.
    Type: Application
    Filed: May 29, 2024
    Publication date: October 31, 2024
    Applicant: Ipsen Biopharm Ltd.
    Inventors: Eliel Bayever, Sarah F. Blanchette, Jonathan Basil Fitzgerald, Daniel F. Gaddy, Bart S. Hendriks, Ashish Kalra, Helen Lee
  • Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
    Publication number: 20230062425
    Abstract: Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.
    Type: Application
    Filed: April 1, 2022
    Publication date: March 2, 2023
    Applicant: Ipsen Biopharm Ltd.
    Inventors: Eliel Bayever, Sarah F. Blanchette, Jonathan Basil Fitzgerald, Daniel F. Gaddy, Bart S. Hendriks, Ashish Kalra, Helen Lee
  • Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
    Patent number: 11344552
    Abstract: Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: May 31, 2022
    Inventors: Eliel Bayever, Sarah F. Blanchette, Jonathan Basil Fitzgerald, Daniel F. Gaddy, Bart S. Hendriks, Ashish Kalra, Helen Lee
  • Compositions and methods for non-invasive imaging
    Patent number: 9968694
    Abstract: The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: May 15, 2018
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Thomas Wickham, Bart S. Hendriks, Samuel Agresta, Helen Lee, Daniel F. Gaddy
  • Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
    Publication number: 20180078556
    Abstract: Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.
    Type: Application
    Filed: November 10, 2017
    Publication date: March 22, 2018
    Inventors: Eliel Bayever, Sarah F. Blanchette, Jonathan Basil Fitzgerald, Daniel F. Gaddy, Bart S. Hendriks, Ashish Kalra, Helen Lee
  • Combination therapy for treating HER2-positive cancers
    Patent number: 9913901
    Abstract: Methods for treating cancer patients with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of (i) an anthracycline-loaded immunoliposome with a targeting moiety that is a first anti-HER2 antibody and (ii) an anti-cancer therapeutic comprising a second anti-HER2 antibody.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: March 13, 2018
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Victor Moyo, Bart S. Hendriks, Thomas Wickham, Elena Geretti, Joseph G. Reynolds, Christopher W. Espelin
  • COMBINATION THERAPIES FOR TREATING HER2-POSITIVE CANCERS THAT ARE RESISTANT TO HER2-TARGETED THERAPIES
    Publication number: 20170258903
    Abstract: Methods for treating cancer patients (e.g., cancer patients resistant or intolerant to pertuzumab and ado-trastuzumab emtansine) with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of a doxorubicin-loaded immunoliposome with a targeting moiety that is an anti-HER2 antibody that is not an inhibitor of HER2 signaling and an anti-cancer therapeutic comprising a doxorubicin-free anti-cancer therapeutic comprising a different anti-HER2 antibody.
    Type: Application
    Filed: May 18, 2017
    Publication date: September 14, 2017
    Applicant: Merrimack Pharmaceuticals, Inc.
    Inventors: Christopher W. Espelin, Elena Geretti, Bart S. Hendriks, Victor Moyo, Joseph G. Reynolds, Thomas Wickham
  • DOSAGE AND ADMINISTRATION FOR PREVENTING CARDIOTOXICITY IN TREATMENT WITH ERBB2-TARGETED IMMUNOLIPOSOMES COMPRISING ANTHRACYCLINE CHEMOTHERAPEUTIC AGENTS
    Publication number: 20170189335
    Abstract: Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.
    Type: Application
    Filed: January 18, 2017
    Publication date: July 6, 2017
    Applicant: Merrimack Pharmaceuticals, Inc.
    Inventors: Joseph G. Reynolds, Kenneth J. Olivier, JR., Bart S. Hendriks, Thomas Wickham, Stephan Klinz, Elena Geretti
  • Dosage and administration for preventing cardiotoxicity in treatment with ERbB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents
    Patent number: 9610249
    Abstract: Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: April 4, 2017
    Assignee: Merrimack Pharmaceuticals. Inc.
    Inventors: Joseph G. Reynolds, Kenneth J. Olivier, Jr., Bart S. Hendriks, Thomas Wickham, Stephan Klinz, Elena Geretti
  • MARKER QUANTITATION IN SINGLE CELLS IN TISSUE SECTIONS
    Publication number: 20170082630
    Abstract: Improved assays incorporating single-cell based image analysis that enable quantitation of expression of individual cellular proteins and heterogeneity in terms of individual cellular protein molecule numbers per cell at the single cell level and mapped across sections of clinical tissue samples are disclosed.
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Inventors: Bart S. Hendriks, Elena Geretti, Arthur J. Kudla, Matthew David Onsum, Violette Paragas, Sharon Moulis
  • Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
    Publication number: 20170049775
    Abstract: Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.
    Type: Application
    Filed: August 19, 2016
    Publication date: February 23, 2017
    Inventors: Eliel Bayever, Sarah F. Blanchette, Jonathan Basil Fitzgerald, Daniel F. Gaddy, Bart S. Hendriks, Ashish Kalra, Helen Lee
  • Compositions and methods for non-invasive imaging
    Patent number: 9511155
    Abstract: The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: December 6, 2016
    Assignee: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Thomas Wickham, Bart S. Hendriks, Samuel Agresta, Helen Lee, Daniel F. Gaddy
  • COMBINATION THERAPY FOR TREATING HER2-POSITIVE CANCERS
    Publication number: 20160250328
    Abstract: Methods for treating cancer patients with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of (i) an anthracycline-loaded immunoliposome with a targeting moiety that is a first anti-HER2 antibody and (ii) an anti-cancer therapeutic comprising a second anti-HER2 antibody.
    Type: Application
    Filed: December 3, 2013
    Publication date: September 1, 2016
    Inventors: Victor Moyo, Bart S. Hendriks, Thomas Wickham, Elena Geretti, Joseph G. Reynolds, Christopher W. Espelin
  • DOSAGE AND ADMINISTRATION FOR PREVENTING CARDIOTOXICITY IN TREATMENT WITH ERBB2-TARGETED IMMUNOLIPOSOMES COMPRISING ANTHRACYCLINE CHEMOTHERAPEUTIC AGENTS
    Publication number: 20160038417
    Abstract: Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.
    Type: Application
    Filed: August 21, 2015
    Publication date: February 11, 2016
    Inventors: JOSEPH G. REYNOLDS, Kenneth J. Olivier, Bart S. Hendriks, Thomas Wickham, Stephan Klinz, Elena Geretti
  • Dosage and administration for preventing cardiotoxicity in treatment with ERBB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents
    Patent number: 9226966
    Abstract: Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: January 5, 2016
    Assignee: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Joseph G. Reynolds, Kenneth J. Olivier, Jr., Bart S. Hendriks, Thomas Wickham, Stephan Klinz, Elena Geretti
  • MARKER QUANTITATION IN SINGLE CELLS IN TISSUE SECTIONS
    Publication number: 20150111217
    Abstract: Improved assays incorporating single-cell based image analyses that enable quantitation of expression of individual cellular proteins and heterogeneity in terms of individual cellular protein molecule numbers per cell at the single cell level and mapped across sections of clinical tissue samples are disclosed.
    Type: Application
    Filed: June 20, 2013
    Publication date: April 23, 2015
    Inventors: Bart S. Hendriks, Elena Geretti, Arthur J. Kudla, Matthew David Onsum, Violette Paragas, Sharon Moulis
  • DOSAGE AND ADMINISTRATION FOR PREVENTING CARDIOTOXICITY IN TREATMENT WITH ERBB2-TARGETED IMMUNOLIPOSOMES COMPRISING ANTHRACYCLIN CHEMOTHERAPEUTIC AGENTS
    Publication number: 20140023698
    Abstract: Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.
    Type: Application
    Filed: June 6, 2013
    Publication date: January 23, 2014
    Inventors: Joseph G. Reynolds, Kenneth J. Olivier, JR., Bart S. Hendriks, Thomas Wickham, Stephan Klinz, Elena Geretti
  • Polymers for delivery of nucleic acids
    Patent number: 6548302
    Abstract: The present invention relates to compositions and methods for delivery of nucleic acids. In particular, the invention provides a polymeric delivery formulation including a nucleic acid to be transfected into a host cell, formulated in a biodegradable polymer having phosphorous-based linkages.
    Type: Grant
    Filed: June 18, 1999
    Date of Patent: April 15, 2003
    Assignee: Johns Hopkins University School of Medicine
    Inventors: Hai-Quan Mao, Kevin Y. Lin, Bart S. Hendriks, Kam W. Leong, Michael F. Haller